Diabetic Med:互助支持对糖尿病困扰的影响如何?

2018-10-29 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于互助支持对糖尿病困扰的影响的整群随机对照试验的研究。调查中国成人2型糖尿病患者中加入常规糖尿病教育时,互助支持是否会减少糖尿病的困扰并改善血糖控制。 研究人员进行了一项集群随机试验,涉及来自南京8个社区的400名2型糖尿病患者。所有参与者每月平均接受医生,经过认证的糖尿病教育者,营养师,心理学家和足病护士2小时的普通教育。同伴支持

近日,国际杂志 《Diabetic Med》上在线发表一项关于互助支持对糖尿病困扰的影响的整群随机对照试验的研究。调查中国成人2糖尿病患者中加入常规糖尿病教育时,互助支持是否会减少糖尿病的困扰并改善血糖控制。

研究人员进行了一项集群随机试验,涉及来自南京8个社区的4002型糖尿病患者。所有参与者每月平均接受医生,经过认证的糖尿病教育者,营养师,心理学家和足病护士2小时的普通教育。同伴支持由经过培训的同伴领导者领导,每月至少一次包括糖尿病知识和技能分享,以及点对点交流。主要结果是在12个月时使用糖尿病困扰表测量糖尿病困扰。次要结果为基线、6个月和12个月时所有参与者收集的结果数据包括空腹血糖,餐后2小时血糖和HbA 1c浓度。

2012年到2013年,每个研究组在基线时有200名参与者。在6个月时,与常规教育组相比,同伴支持的普通教育组减少了与治疗相关的困扰(1.4±0.6 vs 1.2±0.4; P = 0.004)和总困扰(1.3±0.4 vs 1.2±0.3; P = 0.038)。在12个月时,与常规教育组相比,同伴支持的教育组的情绪负担得分(1.2±0.3 vs 1.4±0.6; P = 0.002),医生相关的困扰(1.1±0.3 vs 1.3±0.4; P = 0.001)和总得分(1.2±0.3 vs 1.3±0.4P= 0.002显著降低。同伴支持的通常教育组空腹血糖水平低于6个月(7.5±1.95 vs 8.0±2.2; P = 0.044)和12个月(7.0±2.3 vs 7.6±1.5; P = 0.008)时的常规教育组。

研究表明除了常规教育的好处,互助支持有效减少2型糖尿病的糖尿病困扰。

原始出处:

C. Ju R. ShiL. Yaoet al. Effect of peer support on diabetes distress: a cluster randomized controlled trial

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638817, encodeId=6f05163881ec9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 17:03:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760859, encodeId=92861e6085933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 17 18:03:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970646, encodeId=cdf119e06463b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 29 14:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609255, encodeId=8169160925555, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 31 05:03:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041982, encodeId=3769104198224, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 29 17:03:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638817, encodeId=6f05163881ec9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 17:03:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760859, encodeId=92861e6085933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 17 18:03:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970646, encodeId=cdf119e06463b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 29 14:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609255, encodeId=8169160925555, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 31 05:03:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041982, encodeId=3769104198224, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 29 17:03:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638817, encodeId=6f05163881ec9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 17:03:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760859, encodeId=92861e6085933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 17 18:03:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970646, encodeId=cdf119e06463b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 29 14:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609255, encodeId=8169160925555, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 31 05:03:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041982, encodeId=3769104198224, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 29 17:03:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638817, encodeId=6f05163881ec9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 17:03:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760859, encodeId=92861e6085933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 17 18:03:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970646, encodeId=cdf119e06463b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 29 14:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609255, encodeId=8169160925555, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 31 05:03:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041982, encodeId=3769104198224, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 29 17:03:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638817, encodeId=6f05163881ec9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 17:03:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760859, encodeId=92861e6085933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 17 18:03:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970646, encodeId=cdf119e06463b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 29 14:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609255, encodeId=8169160925555, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 31 05:03:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041982, encodeId=3769104198224, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 29 17:03:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-29 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Prostate Cancer P D:他汀类药物能够减少经历雄激素阻断治疗糖尿病患者的痴呆风险

雄激素阻断治疗(ADT)已经被报道可以增加痴呆的风险,而他汀类药物的使用可以减少痴呆的风险。最近,有研究人员在接受ADT的2型糖尿病(T2DM)患者中,调查了他汀类药物的使用和痴呆之间的相关性。研究总共包括了在1998年到2013年之间新诊断为PCa的9855名T2DM患者,其中5427名患者因PCa接受了雄激素阻断治疗。在倾向性评分匹配之后,1006名他汀类药物使用者和1006名非他汀类药物使用

Eur Heart J:糖尿病对肥厚型心肌病临床表型的影响

由此可见,患有糖尿病的肥厚型心肌病患者年龄较大,心血管风险较高。由于舒张功能障碍,他们具有较低的运动功能,以及会出现较多的心衰症状。

Clin J Am Soc Nephro:ACCORD研究7.7年随访:糖尿病长期强化降压和贝特类药物降脂或致肾损伤

2型糖尿病既是心血管病的危险因素,也显着增加慢性肾脏病发生风险,因此,保护心脏和肾脏对于2型糖尿病患者来说非常重要。对于心血管病高危2型糖尿病患者,降糖、降压、降脂是重要的管理策略,但至于这三项指标降至什么程度最佳,目前仍难确定。

Crit Care:急性低氧呼吸衰竭患者糖尿病与急性呼吸窘迫综合征的相关性研究

由此可见,在一项针对AHRF患者的大型全球观察性研究中,未发现糖尿病与既往患有ARDS、ARDS发生发展或ARDS结局之间存在关联。

糖尿病患者便秘了,能开乳果糖吗?

科里30床的老大娘经常出些难题为难我们,篇幅有限就不一一举例说明了。临床医生大概都经历过,就是那种各种提要求的患者,把医院当成宾馆,医生当成是服务员。不是医生指导患者如何治疗,而是她自己想怎么治疗就怎么治疗。

Diabetes Care:基于大规模中国人群彩色眼底照片的糖尿病视网膜病变自动深度学习算法

糖尿病视网膜病变(Diabetic retinopathy,DR)是糖尿病最常见的微血管并发症,是工作年龄成人不可逆视力丧失的主要原因。 在临床上,甚至有一部分患者的糖尿病是有了视网膜病变之后在眼科门诊发现自己得了糖尿病的。